|
Dr. Hallam joined Palatin in May, 2005 as executive vice president of research & development. He possesses over 20 years of drug discovery and development experience within the pharmaceutical industry.
From 1996 to 2005, Dr. Hallam held key senior management leadership positions within AstraZeneca R&D, including vice president of biologics based out of the UK, vice president of respiratory and inflammation research based in Sweden and vice president of medical affairs within the US. During this time, Dr. Hallam developed and implemented programs to broaden the firm’s portfolio of products, established strategic partner relationships and defined new discovery strategies. From 1985 to 1995, Dr. Hallam served at progressively senior management positions within Smith Kline & French Research, Glaxo Group Research and Roche Research. His accomplishments include development of numerous drug candidates for a variety of indications, including asthma, rheumatoid and osteo-arthritis, multiple sclerosis and transplant rejection.
Dr. Hallam joined the pharmaceutical industry after a post-doctoral fellowship at the Physiological Laboratory, University of Cambridge, UK. He earned his Ph.D. in biochemistry from the University of London and his B.Sc. from the University of Leeds.
| 